Mumbai: Drug firm Wockhardt Ltd on Saturday posted a consolidated net profit of Rs127.5 crore for the second quarter ended 30 September on improved sales in all markets led by the US.
The drug firm had posted a net loss of Rs96.68 crore for the quarter ended September 30, 2010.
The company’s overall sales grew by 18% to Rs1,110.5 crore.
“Wockhardt is showing consistent all-round growth globally,” said Wockhardt Ltd chairman Habil Khorakiwala.
Its business grew 49% during this quarter with its prime products improving market share.
Wockhardt had new approvals for four products in US during the quarter taking the total number of proved products in that market to 84. Its other subsidiary, Morton Grove Pharmaceuticals Inc had 34 approvals till date.
“The infusion of new product launches will see Wockhardt breaking new ground in this market,” the company statement added.
While, its sales grew 13.55%, capturing a market share of 2.03% as compared to 1.94% last year. In the domestic market, the company launched 9 new products in this quarter.
The bulk drug business of Wockhardt more than doubled in the quarter.